Literature DB >> 2879235

Short-term management of nesidioblastosis using the somatostatin analogue SMS 201-995.

P Hindmarsh, C G Brook.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2879235     DOI： 10.1056/NEJM198701223160416

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  7 in total

Review 1.  Changing concepts of islet cell dysplasia in neonatal and infantile hyperinsulinism.

Authors:  C G Thomas; R E Cuenca; R G Azizkhan; L E Underwood; C N Carney
Journal:  World J Surg       Date:  1988-10       Impact factor: 3.352

Review 2.  Clinical use of the long acting somatostatin analogue octreotide in pediatrics.

Authors:  M T Tauber; A G Harris; P Rochiccioli
Journal:  Eur J Pediatr       Date:  1994-05       Impact factor: 3.183

3.  Somatostatin analogue in short term management of hyperinsulinism.

Authors:  J M Kirk; L Di Silvio; P C Hindmarsh; C G Brook
Journal:  Arch Dis Child       Date:  1988-12       Impact factor: 3.791

4.  The effects of a somatostatin analogue on the metabolism of an infant with Beckwith-Wiedemann syndrome and hyperinsulinaemic hypoglycaemia.

Authors:  W J Gerver; P P Menheere; C Schaap; P Degraeuwe
Journal:  Eur J Pediatr       Date:  1991-07       Impact factor: 3.183

Review 5.  Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.

Authors:  P E Battershill; S P Clissold
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

Review 6.  Somatostatin analogues for the treatment of hyperinsulinaemic hypoglycaemia.

Authors:  Basma Haris; Saras Saraswathi; Khalid Hussain
Journal:  Ther Adv Endocrinol Metab       Date:  2020-12-02       Impact factor: 3.565

Review 7.  Somatostatin receptors in congenital hyperinsulinism: Biology to bedside.

Authors:  Mirjam E van Albada; Klaus Mohnike; Mark J Dunne; Indi Banerjee; Stephen F Betz
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-27       Impact factor: 6.055
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.